Search for European Projects

20 European Projects Found

Searched on 125080 European Projects

 FINISHED 

PTX3 in Humoral Innate Immunity (PHII)

Start date: Sep 1, 2015, End date: Aug 31, 2020,

The innate immune system includes a cellular and a humoral arm. Structural diversity is a characteristic of humoral fluid phase pattern recognition molecules. These include complement components, collectins, ficolins, and pentraxins. We have used the long pentraxin PTX3, identified by the applicant (cDNA and genomic, mouse and human), as a prototypic fluid phase pattern recognition molecule to ...
Read Project

 1

 FINISHED 

Generation and maintenance of long-lived memory T cells in humans (PERSYST)

Start date: Sep 1, 2015, End date: Aug 31, 2020,

Defining the molecular mechanisms governing memory T cell differentiation and homeostasis is of pivotal importance to generate durable and protective T cell responses against infections and cancers. Considerable knowledge in this regard has been acquired in mouse models but is still limited about human T cells. In particular, some mechanisms are assumed to occur in humans but were never formally d ...
Read Project

 1

 FINISHED 

European Sepsis Academy: towards new biomarkers to improve sepsis management (ESA -ITN)

Start date: Mar 1, 2016, End date: Feb 29, 2020,

ESA-ITN will break through the state of the art in sepsis diagnostics and will train 15 early-stage researchers (ESRs) to determine the clinical potency of a variety of new complementary sepsis biomarkers. These cover the full range of the antiinflammatory response in sepsis, at genetic, molecular and cellular level. Rapid and practical biomarker diagnostics for sepsis will be developed by buildin ...
Read Project

 7

 FINISHED 

Efficacy and safety of low-dose IL-2 (ld-IL-2) as a Treg enhancer for anti-neuroinflammatory therapy in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients (MIROCALS)

Start date: Sep 1, 2015, End date: Aug 31, 2019,

Amyotrophic Lateral Sclerosis (ALS) is a fatal degenerative disorder of the brain and spinal cord affecting some 40,000 individuals in Europe, causing 11,000 deaths each year. Our pioneering work on riluzole showed that it is possible to modify ALS progression but all subsequent trials of potential neuroprotective agents have failed. Thus, drug development in ALS, including trial design, patient s ...
Read Project

 12

 FINISHED 

Signalling compartmentalization and vesicle Trafficking at the Phagocytic Synapses (STEPS)

Start date: Apr 1, 2013, End date: Mar 31, 2019,

A key feature of the immune response is its specificity and macrophages must be able to discriminate precisely between an infectious stimulus and a non-infectious one and tune their response in accordance with the molecular context in which the target particle is recognized. In recent years, scientists have proposed the concept of the phagocytic synapse, to stress the fact that a particle does not ...
Read Project

 2

 FINISHED 

Epigenetics and microRNAs in Myocardial Function and Disease (CARDIOEPIGEN)

Start date: Oct 1, 2012, End date: Sep 30, 2018,

Heart failure (HF) is the ultimate outcome of many cardiovascular diseases. Re-expression of fetal genes in the adult heart contributes to development of HF. Two mechanisms involved in the control of gene expression are epigenetics and microRNAs (miRs). We propose a project on epigenetic and miR-mediated mechanisms leading to HF.Epigenetics refers to heritable modification of DNA and histones that ...
Read Project

 1

 FINISHED 

Structured and validated training programmes for robotic surgery in the field of urology

Start date: Sep 1, 2015, End date: Aug 31, 2018,

...er Europe. The project will be carried out by the forerunners of robotic surgery in the field of urology. The European Association of Urology (NL), ORSI (BE), the University of Saarland (DE) and the Humanitas Research Hospital (IT) combined their state of the art knowledge and expertise, to develop these training programmes. The partners have a solid track-record on (1) the latest developments in ...
Read Project

 4

 FINISHED 

Innovative nanoparticle formulation for a miR-133 based treatment of cardiac hypertrophy (miRCaP)

Start date: Dec 1, 2016, End date: May 31, 2018,

Innovative nanoparticle formulation for a miR-133 based treatment of cardiac hypertrophyCardiovascular diseases (CDs) are growing problems worldwide, affecting as much as 1% of the population. The causes include ischemic, toxic, genetic, post-inflammatory and structural defects; often multiple etiologies are present within an individual patient germane to the contraction failing, resulting in a mo ...
Read Project

 1

 FINISHED 

Development and Evaluation of Nanomedicines for Cancer Treatment through Immunomodulation: Targeting Tumor-Associated Macrophages (NANOTAM)

Start date: May 20, 2015, End date: May 19, 2017,

This project is focused on the development of novel nanomedicines effective in targeting the immunosuppressive, pro-tumoural, Tumour-Associated Macrophages (TAM) with the aim to manipulate the host’s immune system and improve anti-tumour responses. In most patients, chronic inflammation and immune suppression are the dominant effects in the tumour microenvironment. The infiltration of TAM in tumou ...
Read Project

 1

 FINISHED 

mRNA translational regulation in heart failure (MRNA IN HEART)

Start date: Apr 1, 2014, End date: Aug 29, 2016,

Protein synthesis is among the principal biological processes underlying cardiac hypertrophy, an early event in many forms of heart failure (HF). It is associated with worsening of cardiac function after long-term exposure to noxae. The rate-limiting step of protein synthesis is mRNA translation, which is controlled by factors involved in initiation and/or elongation. 4E-BPs regulate the translati ...
Read Project

 1

 FINISHED 

Improving adoptive T cell transfer immunotherapy for cancer with T memory stem cells (STEMIMMUNE)

Start date: Aug 1, 2012, End date: Jul 31, 2016,

"Here we seek to identify the genetic program at the basis of T memory stem cell persistence in vivo and use their properties to improve the adoptive T cell transfer for the treatment of human cancer. Adoptive cell transfer with tumour-specific T lymphocytes is currently under test in the clinic for the treatment of solid tumours such as melanoma. However, the poor persistence in vivo of adoptivel ...
Read Project

 1

 FINISHED 

ICT-enabled, cellular artificial liver system incorporating personalized patient management and support (d-LIVER)

Start date: Oct 1, 2011, End date: Sep 30, 2015,

d-LIVER applies scenario-driven development methodologies to address an unmet need for bio-artificial liver support via continuous detoxification as remote transient therapy at the Point-of-Need. The liver is a complex organ with various vital functions in synthesis, detoxification and regulation; its failure is life-threatening and the only curative treatment is transplantation. Whilst awaiting t ...
Read Project

 15

 FINISHED 

Role of microRNAs 143 and 145 in cardiovascular physiology and disease: from bench to bedside (From Bench to Bedside)

Start date: Aug 1, 2011, End date: Jul 31, 2015,

Cardiometabolic diseases (CMD) (such as atherosclerosis, hypertension) are the primary cause of death and disability in the Western world. Although lifestyle programmes and therapeutic approaches have significantly reduced the socio-economic burden of CMD, a large number of events still cannot be avoided (residual risk). Neointimal hyperplasia is the principal pathogenic occurrence underlying athe ...
Read Project

 2

 FINISHED 

Global microRNA profiling of normal and Pbx1-null hematopoietic stem cells and progenitors for the identification of new regulators of the balance between self-renewal and differentiation (HSC self-renewal)

Start date: Aug 1, 2010, End date: Mar 18, 2015,

MicroRNAs (miRNAs) are non-coding RNA molecules that repress translation and stability of target mRNAs. They are key regulators of cell cycle and differentiation in embryonic stem cells, and are differentially expressed among many tumors, but their function in adult stem cells (SC) is not known. Somatic SC are able to self-renew, at the same time generating a differentiated progeny that replenish ...
Read Project

 1

 FINISHED 

Characterization of NK cell distributions and functions in human tissues in HIV-1 pathogenesis (CNKHIV)

Start date: Feb 1, 2011, End date: Jan 31, 2015,

"HIV is an urgent global health problem and a safe and effective vaccine is desperately required. Although many studies have shown that the innate immune system, and in particular, natural killer (NK) cells play a central role in determining the quality of the host immune response to HIV -1, the full host beneficial potential of the anti-HIV-1 NK-mediated activity can not be realized in vivo, as N ...
Read Project

 1

 FINISHED 

A Coordinated and Structured International Post-Doctoral Program to Foster Trans-national Mobility and Independent Career of Scientists in Biomedicine (SIPOD)

Start date: Mar 16, 2009, End date: Sep 15, 2014,

"This program encompasses the coordinated action of three major Biomedicine Research Centers and a Biotech shell in Lombardy, to launch a new Structured International Post-Doctoral program (SIPOD). These research centers operate in conjunction with the Scuola Europea di Medicina Molecolare (SEMM) whose aim is to promote the training and research of young scientists within emerging sectors of biome ...
Read Project

 4

 FINISHED 

The humoral innate immune system: long pentraxins as a paradigm (HIIS)

Start date: Jun 1, 2009, End date: May 31, 2014,

"The innate immune system consists of humoral and a cellular arm, but attention has largely been focused on cells and their receptors. The humoral innate immune system (HIIS) is generally represented as a collection of diverse molecules (collectins, ficolins, pentraxins). A tenet underlying this application is that in spite of molecular diversity, the HIIS is built on general principles and logic ...
Read Project

 1

 FINISHED 

Advanced Teaching and TRaining for Adoptive Cell Therapy (ATTRACT)

Start date: Oct 1, 2009, End date: Sep 30, 2013,

Considerable resources are devoted to fighting cancer throughout Europe, yet these efforts are not producing the results that health practitioners and citizens might expect. This is partly due to the fragmentation and duplication of research efforts within Member states and the lack of co-ordination at European level. However it can also be attributed to the need to retain and most importantly dev ...
Read Project

 16

 FINISHED 

"Early diagnosis, treatment and prevention of mood disorders targetting the activated inflammatory response system" (MOODINFLAME)

Start date: Nov 1, 2008, End date: Apr 30, 2013,

"Partners come from 10 European countries to achieve two main objectives: A) The further exploration of 3 animal models (the OBX rat, GS rat and NOD mouse) characterized by an activated immune response system (IRS), an abnormal tryptophan catabolism and a depressive-like behaviour to study the pathogenesis of inflammation-related mood disorders and the efficacy/working mechanism of anti-inflammat ...
Read Project

 21

 FINISHED 

Role of innate immunity in the pathogenesis of autoimmune diseases (RIISPAD)

Start date: Mar 1, 2008, End date: Feb 29, 2012,

"We propose a multidisciplinary “translational research” project that will exploit the molecular and cellular features of innate immunity potentially involved in the pathogenesis of autoimmune diseases in humans. Given the significant scientific advances over the past years in characterizing the physiology of cells from the innate immune system, we will attempt to identify the role of natural kill ...
Read Project

 1